RxDoctor Payments Data

Mimi Sohn, MD

Neurology · Charleston, SCNPI 1275614687

Payments from drug & device makers

$384in general payments, 2019–2025

Across 6 payments — averaging $64.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$263
  • Biohaven Pharmaceuticals, Inc.$101
  • Sunovion Pharmaceuticals Inc.$19

What the payments were for

  • Food & beverage$384100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$384 in reported general payments places this provider in the 35th percentile of 270 neurology providers in South Carolina.

See all neurology providers in South Carolina

Medicare billing

Part B allowed, 2024
$465,073
Medicare patients
120
Services billed
65,769

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Nurtec OdtRimegepant Sulfate312$617,077
UbrelvyUbrogepant189$352,523
Aimovig AutoinjectorErenumab-Aooe85$124,507
Emgality PenGalcanezumab-Gnlm86$116,933
Ajovy AutoinjectorFremanezumab-Vfrm66$78,707
Ajovy SyringeFremanezumab-Vfrm16$30,137
Emgality SyringeGalcanezumab-Gnlm15$27,927
QuliptaAtogepant15$27,795
Topiramate ErTopiramate12$3,243
Sumatriptan Succinate39$2,534
RizatriptanRizatriptan Benzoate58$1,289
Divalproex Sodium22$744
Naratriptan Hcl31$666
Gabapentin22$582
Eletriptan HbrEletriptan Hydrobromide11$428

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy, Qulipta$263$380,317204 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 270 neurology providers in South Carolina.

Other neurology in Charleston

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →